Sharps Compliance (SMED) Tops Q2 EPS by 2c

Sharps Compliance (NASDAQ: SMED) reported Q2 EPS of $0.05, $0.02 better than the analyst estimate of $0.03. Revenue for the quarter came in at $8.7 million versus the consensus estimate of $8.09 million.

David P. Tusa, President and Chief Executive Officer of Sharps, commented, "During the second quarter we delivered strong growth in overall customer billings to $8.7 million, led by solid results in our Retail and Professional markets. Our Retail segment benefitted from strong flu shot activity in the quarter consistent with the increase in the number of flu shots administered in the retail setting. The Professional market billing growth is a result of our continued efforts to educate this market about our mailback solutions. Our Pharmaceutical Manufacturer billings can vary from quarter to quarter, related to the timing of bulk orders for vendor managed inventory programs. Customer billings for this market increased 31% for the fiscal year-to-date period. As expected, we launched one new patient support program for a new drug during the second quarter and we expect to launch three additional patient support programs for new drug therapies as we move through calendar year 2015 and the first half of calendar 2016."

For earnings history and earnings-related data on Sharps Compliance (SMED) click here.

You May Also Be Interested In

• Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
• Integer Holdings Corp (ITGR) Tops Q1 EPS by 2c ; Offers Guidance
• Esquire Financial Holdings, Inc. (ESQ) Tops Q1 EPS by 3c